Addison Advisors’s Quest Diagnostics DGX Stock Holding History

Addison Advisors’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,400	Closed	-$274K	–	775
2026 Q1	$274K	Hold	1,400	–	–	0.06%	181
2025 Q4	$243K	Hold	1,400	–	–	0.05%	189
2025 Q3	$267K	Hold	1,400	–	–	0.06%	184
2025 Q2	$251K	Buy	1,400 +100	+8%	+$17.4K	0.06%	183
2025 Q1	$220K	Hold	1,300	–	–	0.06%	191
2024 Q4	$196K	Buy	1,300 +125	+11%	+$19.4K	0.05%	209
2024 Q3	$182K	Hold	1,175	–	–	0.05%	229
2024 Q2	$161K	Hold	1,175	–	–	0.05%	231
2024 Q1	$156K	Hold	1,175	–	–	0.05%	229
2023 Q4	$162K	Hold	1,175	–	–	0.06%	205
2023 Q3	$143K	Hold	1,175	–	–	0.07%	200
2023 Q2	$165K	Hold	1,175	–	–	0.08%	177
2023 Q1	$166K	Sell	1,175 -3	-0.3%	-$429	0.09%	156
2022 Q4	$184K	Hold	1,178	–	–	0.11%	135
2022 Q3	$145K	Hold	1,178	–	–	0.09%	152
2022 Q2	$157K	Hold	1,178	–	–	0.1%	146
2022 Q1	$161K	Hold	1,178	–	–	0.09%	156
2021 Q4	$204K	Buy	1,178 +3	+0.3%	+$456	0.13%	116
2021 Q3	$171K	Hold	1,175	–	–	0.14%	86
2021 Q2	$155K	Buy	+1,175	New	+$154K	0.13%	97
2020 Q4	$160K	Buy	+1,345	New	+$164K	0.15%	95

Other funds holding DGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

EIG

EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

Addison Advisors's DGX Position: Q2 2026 in Review

Addison Advisors sold out of Quest Diagnostics (DGX) in Q2 2026, closing a stake of 1,400 shares — an estimated $274K sold.

Addison Advisors first reported a position in DGX in Q4 2020 and held it in 21 quarters. The position peaked at $274K in Q1 2026. 1,107 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

Addison Advisors reported no remaining Quest Diagnostics position as of Q2 2026 after selling out during the quarter.
Addison Advisors sold 1,400 Quest Diagnostics shares in Q2 2026, an estimated $274K.
Addison Advisors first reported a position in Quest Diagnostics in Q4 2020 and held it in 21 quarters.
Addison Advisors's Quest Diagnostics position peaked at $274K in Q1 2026.
1,107 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Addison Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.